Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diuretics and renal denervation therapy. 

The Symplicity Catheter System delivers radio frequency energy from within the renal artery to block conduction in the surrounding renal nerves. This counteracts chronic activation of the sympathetic nervous system.

Feature | December 13, 2010 | Dave Fornell

For patients with severe hypertension that remains uncontrolled despite medical therapy, radiofrequency (RF) energy...

News | November 22, 2010

November 22, 2010 – Data presented at the American Heart Association’s Scientific Sessions 2010 showed that...

News | October 20, 2010

October 20, 2010 - The U.S. Food and Drug Administration (FDA) approved a new drug to help prevent stroke...

Technology | October 15, 2010

October 15, 2010 – The U.S. Food and Drug Administration (FDA) has approved an abbreviated new drug...

News | October 07, 2010

October 7, 2010 - Taking medication at night instead of in the morning significantly increases efficacy in keeping...

News | September 29, 2010

September 29, 2010 - Preclinical data of a therapy designed to treat drug-resistant hypertension was presented last...

News | August 30, 2010

August 30, 2010 – According to the results of a late-breaking analysis involving more than 200 000 patients in...

News | August 18, 2010

August 18, 2010 - The U.S. Food and Drug Administration (FDA) today proposed to withdraw approval of the...

News | July 01, 2010

July 1, 2010 – Clinical results have shown the Rheos System is successful in lowering blood pressure, CVRx...

News | June 21, 2010

June 21, 2010 – Long-term data presented today from Ardian’s Symplicity HTN-1 study demonstrate that the...

Technology | June 15, 2010

June 15, 2010 – Health care professionals can now get information on the diagnosis, pathology, and...

A new formulation of Epoprostenol for Injection is stable at room temperature for up to 24 hours when diluted.

News | April 26, 2010

April 22, 2010 — An improved formulation of epoprostenol for the treatment of primary pulmonary arterial...

Technology | April 18, 2010

April 19, 2010 – The U.S. Food and Drug Administration (FDA) recently cleared a generic version of...

Technology | March 23, 2010

March 23, 2010 – The FDA granted approval for diltiazem hydrochloride extended-release tablets to treat...

Feature | March 17, 2010

March 16, 2010 — Lowering blood pressure to normal levels — below currently recommended levels — did not...

Overlay Init